Breaking News Instant updates and real-time market news.

LC

LendingClub

, IBM

IBM

09:41
04/19/17
04/19
09:41
04/19/17
09:41

Unusually active option classes on open April 19th

Unusual total active option classes on open include: LendingClub (LC), IBM (IBM), Bristol Myers Squibb (BMY), Baidu (BIDU), Applied Materials (AMAT), Morgan Stanley (MS), S&P 500 Index (.SPX), Coca Cola (KO), Goldman Sachs (GS), and Financial Sector SPDR (XLF).

LC

LendingClub

IBM

IBM

BMY

Bristol-Myers

BIDU

Baidu

$174.47

1.16 (0.67%)

AMAT

Applied Materials

$38.05

0.03 (0.08%)

MS

Morgan Stanley

SPX

S&P 500

KO

Coca-Cola

GS

Goldman Sachs

XLF

Financial Select Sector

  • 25

    Apr

  • 26

    Apr

  • 27

    Apr

  • 27

    Apr

  • 02

    May

  • 03

    May

  • 04

    May

  • 09

    May

  • 09

    May

  • 22

    May

  • 30

    May

  • 06

    Jun

  • 18

    Jul

  • 17

    Oct

LC LendingClub

03/22/17
WEDB
03/22/17
UPGRADE
Target $5
WEDB
Neutral
LendingClub upgraded to Neutral from Underperform at Wedbush
Wedbush analyst Henry Coffey upgraded LendingClub to Neutral saying management has made a very good case in recent meetings on how they will enhance the breadth of the marketplace and grow volumes. Coffey is holding his 2017-18 adjusted estimates at current levels and introduced a 2019 earnings estimate of 34c and refocusing his price target methodology on simply 2019E adjusted EBITDA, resulting in an increase in his price target to $5 from $4.50.
04/19/17
STFL
04/19/17
INITIATION
STFL
Hold
LendingClub coverage resumed with a Hold at Stifel
Stifel analyst John Davis resumed coverage of LendingClub with a $6 price target and a Hold rating.
03/16/17
GUGG
03/16/17
UPGRADE
Target $7
GUGG
Buy
LendingClub upgraded to Buy from Neutral at Guggenheim
Guggenheim analyst Eric Wasserstrom upgraded LendingClub to Buy with a $7 price target.
03/22/17
03/22/17
UPGRADE

On The Fly: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. KeyBanc analyst Todd Thomas upgraded Urban Outfitters (URBN) to Overweight from Sector Weight, saying the retailer has a highly differentiated product offering and has made significant investments to capture e-commerce share. 2. Deutsche Bank analyst Rod Lache upgraded BorgWarner (BWA) to Buy from Hold, saying the prospects for business units focused on Internal Combustion efficiency and emissions are better than he previously thought. The analyst expects penetration of battery electric vehicles will remain "relatively low" through the 2020s. He raised his price target for BorgWarner shares to $51 from $41. The analyst this morning also raised his price target for Buy-rated Delphi (DLPH) to $99 from $88 and Hold-rated Tenneco (TEN) to $78 from $75. 3. UBS analyst Julien Dumoulin-Smith upgraded Sunrun (RUN) to Buy from Neutral, citing accelerating prospects amid policy support in the Northeast. 4. Wedbush analyst Henry Coffey upgraded LendingClub (LC) to Neutral from Underperform, saying management has made a very good case in recent meetings on how they will enhance the breadth of the marketplace and grow volumes. 5. Credit Suisse analyst Andre Natal upgraded Petrobras (PBR) to Outperform with an $11 price target saying recent share weakness provides a buying opportunity. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
IBM IBM

04/19/17
LEHM
04/19/17
NO CHANGE
Target $141
LEHM
Underweight
IBM shares likely to see pressure in near-term, says Barclays
Barclays analyst Mark Moskowitz expects shares of IBM to be under pressure in the near-term following last night's Q1 results. The "major" year-over-year deterioration in gross margin and IBM's dependence on discrete items to pad earnings are likely to frustrate investors, Moskowitz tells investors in a post-earnings research note. He lowered his price target for the shares to $141 from $144 and keeps an Underweight rating on the name.
04/19/17
STFL
04/19/17
NO CHANGE
STFL
IBM should be bought below $160, says Stifel
Stifel analyst David Grossman says that there were some negative data points in IBM's Q1 report, including the year-over-year decline in its gross margin, the deceleration of its Technology Services/Cloud segment, and the failure of its GBS unit to show meaningful improvement. Grossman expects the stock "to struggle" over the next three months, but he thinks that the company is positioning itself well to grow over the longer term, and he continues to believe that the company is differentiated by its ability "to solve specific business problems in specific vertical markets." He recommends buying the shares "on any sustained weakness, particularly below $160."
04/19/17
MSCO
04/19/17
NO CHANGE
Target $212
MSCO
Overweight
IBM catalysts for 2H inflection remain intact, says Morgan Stanley
Morgan Stanley analyst Katy Huberty lowered IBM's Q2 earnings estimate on delayed services signing but said the upcoming mainframe cycle leaves the full year unchanged. The analyst said the mainframe launch later in the year provides a boost to growth and profits, and said investments to transition to a cognitive and cloud platform are largely in place today and are underestimated by investors. Huberty believes catalysts for a 2H inflection remain intact and reiterates an Overweight rating and $212 price target on IBM shares.
04/19/17
JEFF
04/19/17
NO CHANGE
Target $135
JEFF
Underperform
IBM price target lowered to $135 from $145 at Jefferies
Jefferies analyst James Kisner lowered his price target for IBM shares to $135 saying last night's earnings results were "poor quality" given the large contribution from intellectual property income and an artificially low tax rate. The analyst views the quarter as supporting his view that IBM's recently poor earning quality "masks ongoing secular headwinds that will likely result in disappointment for investors." He reiterates an Underperform rating on IBM. The stock in premarket trading is down 5% to $161.12.
BMY Bristol-Myers

03/08/17
PIPR
03/08/17
NO CHANGE
Target $60
PIPR
Neutral
Piper views near-term takeout of Bristol-Myers as unlikely
In a research note titled "Lung Data to Define Value....Not M&A Talk," Piper Jaffray analyst Richard Purkiss contends that news reports suggesting Bristol-Myers (BMY) is a takeover target are "wide of the mark." Industry buyers are unlikely to show interest ahead of the immuno-oncology data readouts in the next 12 months, Purkiss tells investors. He believes the key value-defining events for Bristol over the next year are the four large I/O Combo studies set to read out from mid-2017: AstraZeneca's (AZN) MYSTIC, Merck's (MRK) KN-189, Roche's (RHHBY) IMpower 150 and the company's own CheckMate-227. Ahead of these data, it is virtually impossible to assign a stable fair value to Bristol's I/O franchise, Purkiss argues. He believes investors seeking to benefit from industry consolidation in the near-term should own small- or mid-cap oncology companies. The analyst has a Neutral rating on Bristol with a $60 price target. The stock closed yesterday down 64c to $56.33.
04/03/17
JPMS
04/03/17
NO CHANGE
JPMS
Overweight
Incyte trial news 'another clear positive,' says JPMorgan
JPMorgan analyst Cory Kasimov views the announcement of epacadostat and nivolumab combo moving into Phase 3 studies in first-line non-small cell lung cancer as well as first-line head and neck cancer in 2017 as "another clear positive" for Incyte (INCY). The stock in early trading is up 5% to $140.73. The news expands the breadth of the epacadostat combinations beyond just Merck (MRK) and could ease fears that Bristol-Myers (BMY) is only focused on its internal molecule, Kasimov tells investors in a research note. The analyst continues to be encouraged by Incyte's progress in immuno-oncology and keeps an Overweight rating on the shares.
04/04/17
RBCM
04/04/17
NO CHANGE
RBCM
Incyte price target raised to $157 from $138 at RBC Capital
RBC Capital analyst Simos Simeonidis raised his price target on Incyte (INCY) after Incyte and Bristol-Myers (BMY) announced that they would conduct Phase III trials of the combination of Incyte's epacadostat and Bristol-Myers' Opdivo in 1L lung and head-and-neck cancer. The analyst notes that Merck last week made a similar announcement regarding the use of epacadostat and Merck's Keutruda in additional Phase III trials. Simeonidis keeps an Outperform rating on Incyte.
04/03/17
LEER
04/03/17
NO CHANGE
Target $141
LEER
Outperform
Incyte price target raised to $141 from $130 at Leerink
Leerink analyst Michael Schmidt raised his price target for Incyte (INCY) to $141 from $130 as he sees epacadostat better positioned in the emerging IO combination landscape. The analyst notes that the company and Bristol-Myers (BMY) have announced that both companies will advance the combination of Opdivo and epacadostat into several registration trials in 2017. He reiterates an Outperform rating on Incyte's shares.
BIDU Baidu
$174.47

1.16 (0.67%)

04/18/17
BNCH
04/18/17
INITIATION
Target $190
BNCH
Buy
Baidu initiated with a Buy at Benchmark
Benchmark analyst Fawne Jiang initiated Baidu with a Buy rating and $190 price target.
01/17/17
MSCO
01/17/17
DOWNGRADE
Target $185
MSCO
Equal Weight
Baidu downgraded to Equal Weight at Morgan Stanley
As previously reported, Morgan Stanley downgraded Baidu to Equal Weight from Overweight. Analyst Grace Chen assumed coverage on shares with an Equal Weight rating and a $185 price target saying she expects the recovery will be mild as marketers explore newer media such as video ads.
02/24/17
STFL
02/24/17
NO CHANGE
STFL
Baidu search reached positive turning point, says Stifel
Stifel analyst George Askew says that Baidu's search business reached a positive turning point in Q4, as the business' revenue and customer count both rebounded. However, the analyst says that the doubling of content costs at iQiyi "more than offsets" search's positive impact on the company's margins. He expects Baidu's overall margins to decline this year, but he says that the company has a number of "compelling opportunities," including newsfeed and AI. The analyst keeps a $220 price target and a Buy rating on the shares.
03/28/17
LEHM
03/28/17
INITIATION
Target $195
LEHM
Equal Weight
Baidu initiated with an Equal Weight at Barclays
Barclays analyst Gregory Zhao initiated Baidu with an Equal Weight and a $195 price target.
AMAT Applied Materials
$38.05

0.03 (0.08%)

02/14/17
BOFA
02/14/17
NO CHANGE
BOFA
Applied Materials still worth owning despite rally, says BofA/Merrill
BofA/Merrill analyst Krish Sankar says that Applied Materials' stock is still worth owning despite the 73% surge in the stock over the last year. Specifically, the analyst says that semicap fundamentals remain strong, while organic LED growth, in which the company is a major player, "is just beginning." Moreover, the company should benefit from ramping Chinese investments in semiconductors and its EPS could reach $4 in two years, according to the analyst. He keeps a $40 price target and a Buy rating on the shares.
02/13/17
COWN
02/13/17
NO CHANGE
Target $40
COWN
Outperform
Applied Materials price target raised to $40 from $33 at Cowen
Cowen analyst Timothy Arcuri raised his price target to $40 from $33 on Applied Materials ahead of Q4 results. The analyst sees strong better than expected results, maintenance of market share, and guidance that should support is new price target. Arcuri reiterated his Outperform rating on Applied Materials shares.
01/23/17
DBAB
01/23/17
NO CHANGE
Target $36
DBAB
Buy
Applied Materials near-term upside is likely, says Deutsche Bank
Deutsche Bank analyst Sidney Ho believes Applied Materials is again well-positioned to outgrow the WFE market in 2017. Positive data points from preannouncements in the semicap supply chain suggest near-term upside is likely, Ho tells investors in a research note. The analyst raised his price target for Applied Materials shares to $36 from $33 and reiterates a Buy rating on the shares.
01/25/17
SBSH
01/25/17
NO CHANGE
SBSH
Citi moves Lam Research to top pick in SemiCap Equipment
Citi analyst Atif Mali moved Lam Research (LRCX) to his top pick in Semiconductor Capital Equipment citing his call for outsized memory spend growth in 2017. Applied Materials (AMAT) moves to Mali's number two pick from one. The analyst raised his price target for Lam shares to $135 from $123 and keeps a Buy rating on the name. He keeps a Buy rating on AMAT with a $43 price target and also upped his target for Hold-rated KLA-Tencor (KLAC) to $84 from $74. Mali expects equipment fundamentals to remain strong.
MS Morgan Stanley

04/06/17
EVER
04/06/17
NO CHANGE
EVER
Glass-Steagall return wouldn't find support in Congress, says Evercore ISI
After media reports claimed White House economic adviser Gary Cohn supports rules to make banks split their consumer lending units from their investment divisions, which hints at a return of the "Glass-Steagall" law that was ended by President Clinton and a Republican Congress in 1999, Evercore ISI analyst Terry Haines said there is little support in Congress for a return of the law. Any new bank regulations can't "be done with the stroke of a pen" and will have to go through the usual regulatory process, added Haines. Publicly traded large banks include Bank of America (BAC), Citi (C), Goldman Sachs (GS), JPMorgan (JPM), Morgan Stanley (MS), U.S. Bancorp (USB) and Wells Fargo (WFC).
04/04/17
04/04/17
NO CHANGE

Mrogan Stanley recommends buying large banks on weakness after Q1 results
Morgan Stanley analyst Betsy Graseck expects most large banks she covers to report weaker than expected Q1 results. However, the analyst recommends that investors buy the large-cap bank stocks on weakness, as she expects them to benefit from "stronger capital return, easing regulation, lower taxes and higher rates in 2H17," along with an improved GDP outlook and strong expense management. Graseck identifies Citi (C) as her top pick heading into the quarter, as she expects its Q1 results to beat expectations, driven by strength in emerging markets and "repositioning investments" that have started to beat fruit. She expects the bank to get a boost from CCAR in June and says that it is "the biggest beneficiary of easing regulation." Other publicly traded companies in the space include Bank of America (BAC), Goldman Sachs (GS), JPMorgan (JPM), Morgan Stanley (MS), U.S. Bancorp (USB) and Wells Fargo (WFC).
03/29/17
03/29/17
UPGRADE

On The Fly: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Morgan Stanley (MS) upgraded to Buy from Hold at Deutsche Bank with analyst Matt O'Connor citing the recent 10% pullback in the shares and his optimism for capital markets beyond the first quarter. 2. Capital One (COF) upgraded to Buy from Neutral at Nomura with analyst Bill Carcache saying most card issuers have reduced their sub-prime exposure since 2011, but Capital One has increased its subprime mix by 500 bps and is positioned to reap the rewards. Carcache expects Capital One's net income and earning to inflect in 2017 and 2018 with healthy high-single-digit card loan growth continuing, while the need to build reserves abates. The analyst adds, even with no Trump tax or regulatory policy tailwinds, Capital One should put up double-digit earnings growth in 2017 and 2018. 3. Ericsson (ERIC) upgraded to Outperform from Market Perform at Bernstein with analyst Pierre Ferragu saying the company's restructuring plan skews the risk/reward to the upside. 4. Chemours (CC) upgraded to Buy from Hold at Jefferies with analyst Laurence Alexander saying while the stock has rallied as a trade on cyclical leverage and litigation relief, structural improvements in TiO2 and fluoropolymers could bring further upside. 5. Vertex (VRTX) upgraded to Outperform from Market Perform at BMO Capital. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
03/29/17
DBAB
03/29/17
UPGRADE
Target $47
DBAB
Buy
Morgan Stanley upgraded to Buy from Hold at Deutsche Bank
Deutsche Bank analyst Matt O'Connor upgraded Morgan Stanley (MS) to Buy citing the recent 10% pullback in the shares and his optimism for capital markets beyond Q1. Continued successful execution within FICC will support a higher multiple, O'Connor tells investors in a research note. He raised his price target for Morgan Stanley shares to $47 from $43. Goldman Sachs (GS) and Wells Fargo (WFC) are the analyst's other top picks among the U.S. Banks.
SPX S&P 500

09/06/16
MSCO
09/06/16
NO CHANGE
MSCO
S&P 500 price target raised to 2,300 from 2,200 at Morgan Stanley
Morgan Stanley analysts led by Adam Parker raised its 12 month price target on the S&P 500 to 2,300 from 2,200, bull case to 2,500 from 2,400, and bear case to 1,800 from 1,600.
11/01/16
11/01/16
NO CHANGE

S&P 500 breaks support at 2100
The index was last at 2098.91, down over 1.2% on the day. At current price next support is at 2091.75. Resistance is at the 2110 area. A prior note had an incorrect support level of 1991.68, which this note corrects.
04/10/17
MSCO
04/10/17
NO CHANGE
MSCO
Morgan Stanley sets S&P 500 'base case' price target of 2,700
Morgan Stanley U.S. Equity Strategist Michael Wilson set a 12-month "base case" price target of 2,700 for the S&P 500, stating that market technicals are in "very good shape" and institutional and retail data suggest U.S. equity positioning is not extreme. A cyclical upturn began a year ago as the global business cycle bottomed in Q1 of 2016 and President Trump's election then "turbocharged" that cycle, said Wilson.
03/08/17
03/08/17
NO CHANGE

David Tepper says stock market on multiple basis 'kind of full'
Appaloosa Management's David Tepper is speaking in CNBC.
KO Coca-Cola

04/19/17
FBCO
04/19/17
UPGRADE
FBCO
Outperform
Coca-Cola upgraded to Outperform from Neutral at Credit Suisse
Credit Suisse analyst Laurent Grandet upgraded Coca-Cola to Outperform and raised his price target for the shares to $49 from $44. The stock closed yesterday up 41c to $43.48. With incoming CEO James Quincey taking over on May 1, and the refranchising nearly complete, Coca-Cola "has all the pieces in place to be successful again," Grandet tells investors in a research note. The company has "significant balance sheet flexibility" to invest in the business and fill the gaps in the current portfolio, the analyst adds.
02/13/17
RBCM
02/13/17
NO CHANGE
RBCM
Coca-Cola results 'encouraging,' says RBC Capital
RBC Capital analyst Nik Modi says that Coca-Cola's results were "encouraging," especially in North America. The analyst adds that the results were "particularly encouraging" compared with the company's "mega-cap peers." He keeps a $49 price target and an Outperform rating on the shares.
02/22/17
RBCM
02/22/17
NO CHANGE
RBCM
PepsiCo a more likely target of Kraft Heinz than Coca-Cola, says RBC Capital
RBC Capital analyst Nik Modi says that PepsiCo (PEP) is a more likely takeover target for Kraft Heinz (KHC) and 3G than Coca-Cola (KO). The latter company's refranchising initiative creates a "poison pill" because it limits the ability of acquirers to control the company's costs, according to Modi. Additionally, 3G could easily spin off Pepsi Beverages and potentially look to merge it with Kraft Heinz, Modi believes.
03/21/17
JPMS
03/21/17
INITIATION
Target $43
JPMS
Neutral
Coca-Cola initiated with a Neutral at JPMorgan
JPMorgan analyst Andrea Teixeira started Coca-Cola with a Neutral rating and $43 price target.
GS Goldman Sachs

04/19/17
SBSH
04/19/17
UPGRADE
Target $225
SBSH
Neutral
Goldman Sachs upgraded to Neutral from Sell at Citi
Citi analyst Keith Horowitz upgraded Goldman Sachs to Neutral saying yesterday's post-earnings selloff took out the excess valuation premium. The analyst believes the risk/reward is now more balanced. He keeps a $225 price target for Goldman shares.
04/19/17
ARGS
04/19/17
NO CHANGE
ARGS
Goldman Sachs reported 'solid' Q1 results, says Argus
Argus analyst Stephen Biggar says that Goldman reported "solid" Q1 results, but he says that earnings expectations for the company were "inflated,." Biggar thinks that the company faces difficult comparisons in some of its business lines after reporting strong 2016 results. He keeps a Hold rating on the shares.
04/18/17
RAFF
04/18/17
DOWNGRADE
RAFF
Hold
Goldman Sachs downgraded to Hold from Buy at Rafferty Capital
Rafferty Capital analyst Richard Bove downgraded Goldman Sachs to Hold following the company's Q1 results.
04/18/17
NOMU
04/18/17
NO CHANGE
Target $220
NOMU
Neutral
Nomura Instinet expects 'significant pressure' on Goldman shares
In a post-earnings research note titled "No Sense in Sugarcoating It...," Nomura Instinet analyst Steven Chubak says he expects "significant pressure" on shares of Goldman Sachs following the company's disappointing Q1 results. Given the stronger than expected trading results at peers, Goldman's FICC results were "very surprising" and the "biggest source of disappointment," Chubak tells investors in a research note. The analyst expects consensus estimates to be cut meaningfully and keeps a Neutral rating on Goldman shares with a $220 price target. The stock in premarket trading is down 3% to $219.32.
XLF Financial Select Sector

TODAY'S FREE FLY STORIES

UNH

UnitedHealth

$203.89

10.69 (5.53%)

19:58
10/17/17
10/17
19:58
10/17/17
19:58
Recommendations
UnitedHealth analyst commentary  »

UnitedHealth price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Oct

19:25
10/17/17
10/17
19:25
10/17/17
19:25
Conference/Events
The Heritage Foundation hosts President Trump »

President Trump speaks at…

SINA

Sina

$114.26

-0.73 (-0.63%)

19:18
10/17/17
10/17
19:18
10/17/17
19:18
Hot Stocks
Aristeia: Sina claims 'inaccurate' and 'misleading' »

Aristeia Capital, a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 03

    Nov

CLDR

Cloudera

$15.51

0.13 (0.85%)

, HTHIY

Hitachi

$75.56

-0.49 (-0.64%)

18:57
10/17/17
10/17
18:57
10/17/17
18:57
Hot Stocks
Cloudera, Hitachi form strategic partnership »

Cloudera (CLDR) announced…

CLDR

Cloudera

$15.51

0.13 (0.85%)

HTHIY

Hitachi

$75.56

-0.49 (-0.64%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PNFP

Pinnacle Financial

$65.15

-1.15 (-1.73%)

18:35
10/17/17
10/17
18:35
10/17/17
18:35
Earnings
Pinnacle Financial reports Q3 adjusted EPS 90c, consensus 74c »

Reports Q3 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Oct

  • 15

    Nov

FULT

Fulton Financial

$18.95

-0.3 (-1.56%)

18:07
10/17/17
10/17
18:07
10/17/17
18:07
Hot Stocks
Fulton Financial sees FY17 loans & deposits growth mid to high single digits »

Sees FY17 non-interest…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Oct

  • 01

    Nov

  • 02

    Nov

EXXI

Energy XXI

$8.59

-0.41 (-4.56%)

18:07
10/17/17
10/17
18:07
10/17/17
18:07
Hot Stocks
Energy XXI provides operational update on Hurricane Nate impact »

Energy XXI provided an…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FULT

Fulton Financial

$18.95

-0.3 (-1.56%)

18:07
10/17/17
10/17
18:07
10/17/17
18:07
Hot Stocks
Fulton Financial cuts Q4 net interest margin view to up 2-6 bp from 3-9 »

Cuts Q4 non-interest…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Oct

  • 01

    Nov

  • 02

    Nov

HGV

Hilton Grand Vacations

$39.83

0.05 (0.13%)

17:45
10/17/17
10/17
17:45
10/17/17
17:45
Hot Stocks
Hilton Grand Vacations acquires Sunrise Lodge, terms not disclosed »

Hilton Grand Vacations…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 30

    Nov

PRGX

PRGX Global

$6.80

0.05 (0.74%)

, KR

Kroger

$20.48

0.04 (0.20%)

17:42
10/17/17
10/17
17:42
10/17/17
17:42
Hot Stocks
PRGX Global signs multi-year technology services contract with Kroger »

PRGX Global (PRGX) signed…

PRGX

PRGX Global

$6.80

0.05 (0.74%)

KR

Kroger

$20.48

0.04 (0.20%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 30

    Nov

  • 14

    Dec

UBFO

United Security Bank

$9.50

-0.05 (-0.52%)

17:38
10/17/17
10/17
17:38
10/17/17
17:38
Earnings
United Security Bank reports Q3 EPS 16c versus 12c in year-ago period »

Reports Q3 NII $8.2M…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

UBSH

Union Bankshares

$35.32

-0.18 (-0.51%)

, XBKS

Xenith Bankshares

$32.77

-0.07 (-0.21%)

17:35
10/17/17
10/17
17:35
10/17/17
17:35
Hot Stocks
Xenith Bankshares merger into Union Bankshares receives regulatory approval »

Union Bankshares (UBSH)…

UBSH

Union Bankshares

$35.32

-0.18 (-0.51%)

XBKS

Xenith Bankshares

$32.77

-0.07 (-0.21%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Oct

  • 15

    Nov

OMAB

OMA Airports

$41.34

0.28 (0.68%)

17:35
10/17/17
10/17
17:35
10/17/17
17:35
Hot Stocks
OMA Airports reports Q3 terminal passenger traffic up 1.3% »

Aeronautical revenues per…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

IBM

IBM

$146.54

-0.29 (-0.20%)

17:34
10/17/17
10/17
17:34
10/17/17
17:34
Earnings
IBM sees $2.8B-$2.9B increase in Q4 sales from Q3 »

Sees $300M-$400M boost…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Oct

  • 22

    Oct

  • 15

    Nov

OMAB

OMA Airports

$41.34

0.28 (0.68%)

17:33
10/17/17
10/17
17:33
10/17/17
17:33
Earnings
OMA Airports reports Q3 EPS 66c, consensus 70c »

Reports Q3 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SCSS

Select Comfort

$30.38

-0.17 (-0.56%)

17:33
10/17/17
10/17
17:33
10/17/17
17:33
Hot Stocks
Breaking Hot Stocks news story on Select Comfort »

Select Comfort says sees…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Oct

IBM

IBM

$146.54

-0.29 (-0.20%)

, IBKR

Interactive Brokers

$47.40

-0.32 (-0.67%)

17:32
10/17/17
10/17
17:32
10/17/17
17:32
Hot Stocks
On The Fly: After Hours Movers »

UP AFTER EARNINGS: IBM…

IBM

IBM

$146.54

-0.29 (-0.20%)

IBKR

Interactive Brokers

$47.40

-0.32 (-0.67%)

SSKN

STRATA Skin Sciences

$1.75

-0.04 (-2.23%)

HCLP

Hi-Crush Partners

$8.95

0.25 (2.87%)

SCSS

Select Comfort

$30.38

-0.17 (-0.56%)

NAVI

Navient

$12.20

0.47 (4.01%)

CREE

Cree

$29.34

0.06 (0.20%)

AKTX

Akari Therapeutics

$6.40

-0.08 (-1.23%)

MOBL

MobileIron

$3.80

-0.1 (-2.56%)

FOGO

Fogo De Chao

$12.05

0.1 (0.84%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Oct

  • 17

    Oct

  • 17

    Oct

  • 17

    Oct

  • 18

    Oct

  • 22

    Oct

  • 01

    Nov

  • 15

    Nov

  • 18

    Oct

IBM

IBM

$146.54

-0.29 (-0.20%)

17:32
10/17/17
10/17
17:32
10/17/17
17:32
Hot Stocks
IBM sees increase in gross margin of 2.5 points from Q3 to Q4 »

Says not yet feeling full…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Oct

  • 22

    Oct

  • 15

    Nov

PAYX

Paychex

$62.90

-0.55 (-0.87%)

17:31
10/17/17
10/17
17:31
10/17/17
17:31
Syndicate
Breaking Syndicate news story on Paychex »

Paychex files to sell…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Oct

  • 25

    Oct

VZ

Verizon

$48.40

0.31 (0.64%)

17:24
10/17/17
10/17
17:24
10/17/17
17:24
Hot Stocks
FCC settles New York City E-rate investigation with Verizon »

The Federal…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Oct

  • 01

    Nov

SCSS

Select Comfort

$30.38

-0.17 (-0.56%)

17:20
10/17/17
10/17
17:20
10/17/17
17:20
Hot Stocks
Breaking Hot Stocks news story on Select Comfort »

Select Comfort expects to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Oct

IBM

IBM

$146.54

-0.29 (-0.20%)

17:17
10/17/17
10/17
17:17
10/17/17
17:17
Hot Stocks
IBM: Global business services signings up for 3rd consecutive quarter »

Says cognitive solutions…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Oct

  • 22

    Oct

  • 15

    Nov

IBM

IBM

$146.54

-0.29 (-0.20%)

17:14
10/17/17
10/17
17:14
10/17/17
17:14
Hot Stocks
IBM saw 'strong' Watson growth in Q3 »

Says absorbed $100M…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Oct

  • 22

    Oct

  • 15

    Nov

ODP

Office Depot

$3.76

-0.02 (-0.53%)

17:13
10/17/17
10/17
17:13
10/17/17
17:13
Hot Stocks
Office Depot's Allison sells 360,000 common shares »

In a regulatory filing,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SCSS

Select Comfort

$30.38

-0.17 (-0.56%)

17:12
10/17/17
10/17
17:12
10/17/17
17:12
Hot Stocks
Breaking Hot Stocks news story on Select Comfort »

Select Comfort says…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Oct

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.